Therefore, we recommend timely repeat biopsies for patients who develop resistance to EGFR-TKI therapy, particularly those with concurrent EGFR/RB1/TP53 mutations in NSCLC, in order to obtain the best treatment strategies to further extend patient survival and improve quality of life. The gene discussed is RB1; the disease is non-small cell lung carcinoma.